This study evaluated the efficacy of pembrolizumab monotherapy response rate and progression-free survival and its tolerabilty in advanced non-small cell lung cancer patients. Thirty patients with lung cancer in metastatic or recurrent settings were treated with pembrolizumab monotherapy at Hanoi Medical University Hospital from October 2017 to October 2021. |